WO2000050464A1 - Fucogalactane sulfate - Google Patents
Fucogalactane sulfate Download PDFInfo
- Publication number
- WO2000050464A1 WO2000050464A1 PCT/JP2000/000965 JP0000965W WO0050464A1 WO 2000050464 A1 WO2000050464 A1 WO 2000050464A1 JP 0000965 W JP0000965 W JP 0000965W WO 0050464 A1 WO0050464 A1 WO 0050464A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sulfated
- molecular weight
- present
- fucogalactan
- enzyme
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
Definitions
- the present invention provides a sulfated fucogalatatan useful as a reagent for sugar chain engineering, a low molecular weight product derived from the sulfated polysaccharide, and a method for producing the same, a sulfated fucogalatatan degrading enzyme useful in the field of sugar chain engineering, and a method for producing the enzyme About.
- Brown algae contain many types of sulfated fucose-containing polysaccharides.
- 1 sulfated fuhifucan containing only fucose and sulfate groups 2 sulfated fucodarcuronomannan containing glucuronic acid, mannose, fucose, and sulfate groups, for example, sulfate-containing fucose described in W097 / 26896
- the sulfated fucose-containing polysaccharides of brown algae are often not directly separated, but their biological activities are often examined as they are, and the sulfated fucose-containing polysaccharide responsible for the found biological activity is determined. It was difficult.
- the method of utilizing enzymatic degradation for structural analysis of polysaccharides and production of oligosaccharides is the most efficient method.
- the polysaccharide is converted to a low-molecular weight enzyme, It can be easily separated from other polysaccharides by molecular weight fractionation such as filtration.
- sulfated fucogalactan if there is an enzyme that specifically degrades sulfated fucogalactan, it is easy to analyze the structure of sulfated fucogalactan and to produce sulfated fucogalactan oligosaccharide.
- an object of the present invention is to provide (1) a sugar chain engineering reagent or hepatocyte growth factor
- HGF hepatocyte growth factor
- the inventors of the present application have conducted intensive studies and found that sulfated fucogalactan contained in brown algae, A sulfated fucogalactan degrading enzyme capable of decomposing the sulfated polysaccharide and a method for producing the same have been found. Furthermore, they have found a low molecular weight product of sulfated fucogalactan that can be used as a sugar chain engineering reagent and a method for producing the same, and have completed the present invention.
- the first invention of the present invention relates to a sulfated fucogalatatan or a salt thereof having the following physicochemical properties.
- the sulfated fucogalatatan contains galactose and fucose as constituent sugars, and has a molar ratio of 1: 1 to 6: 1.
- the sulfated fucogalatatan is an essential component of the constituent sugars represented by the following general formula (XI).
- R is H or S_ ⁇ 3 H
- the molecular weight is reduced by the sulfated fucogalatatan-decomposing enzyme of the present invention, and one or more compounds selected from the compounds represented by the following general formulas (I) to (IV) are produced.
- R is H or S_ ⁇ 3 H
- the second invention of the present invention relates to a saccharide compound having a chemical structure selected from the following general formulas (11), (III,) and (IV) or a salt thereof. (II)
- R is H or S0 3 H
- a third invention of the present invention relates to a sulfated fucogalatatan degrading enzyme having the following physicochemical properties.
- the enzyme comprises galactose and fucos as constituent sugars.
- Sulfated fucogalactan or a salt thereof having a molar ratio of 1: 1 to 6: 1 to reduce the molecular weight of the sulfated fucogalactan, and to provide a sulfated galatose or galactose at the reducing end.
- the optimum pH is in the range of about 7 to 9, and the optimum temperature is about 25 to 45 ° C.
- a fourth invention of the present invention provides a sulfated fucogalactan characterized by obtaining the sulfated fucogalactan-decomposing enzyme according to the third invention by acting on a sulfated fucogalactan derived from brown algae or a salt thereof.
- the present invention relates to a method for producing a low molecular weight compound or a salt thereof. Examples of the low molecular weight product obtained by the enzyme include the oligosaccharide or the salt thereof according to the second aspect.
- the fifth invention of the present invention is the sulfate according to the third invention, wherein a bacterium belonging to the genus Flavobacterium having an ability to produce a sulfated fucogalactan degrading enzyme is cultured, and the enzyme is collected from the culture.
- the present invention relates to a method for producing a fucogalactan-decomposing enzyme.
- Figure 1 pH and relative activity of sulfated fucogalatatan degrading enzyme obtained by the present invention
- FIG. 2 is a graph showing the relationship between the temperature and the relative activity (%) of the sulfated fucogalactan degrading enzyme obtained by the present invention.
- FIG. 3 is a view showing the 1 H—NMR spectrum of the sulfated fucogalactan low molecular weight product (A) obtained by the present invention.
- Figure 4 is a diagram showing a 1 3 C-NMR spectrum of the sulfated fucogalactan smaller molecules obtained by the present invention (A).
- FIG. 5 is a diagram showing a mass analysis (mass) spectrum of the sulfated fucogalactan low molecular weight compound (A) obtained by the present invention.
- Figure 7 is a diagram showing a 1 3 C-NMR spectrum of the sulfated fucogalactan smaller molecules obtained by the present invention (B).
- Figure 8 Mass fraction of sulfated fucogalactan low molecular weight compound (B) obtained by the present invention It is a figure which shows an analysis (mass) spectrum.
- FIG. 9 is a diagram showing a 1 H-NMR spectrum of a low molecular weight product of diphthecogalactan sulfate (C) obtained by the present invention.
- FIG. 10 is a diagram showing a 13 C-NMR spectrum of a sulfated low molecular weight fucogalatatan (C) obtained by the present invention.
- FIG. 11 is a view showing a mass spectrometry (mass) spectrum of a sulfated fucogalactan low molecular weight product (C) obtained by the present invention.
- FIG. 12 is a diagram showing a 1 H-NMR spectrum of sulfated low molecular weight fucogalatatan (D) obtained by the present invention.
- FIG. 13 is a diagram showing a 13 C-NMR spectrum of sulfated fucogalactan low molecular weight compound (D) obtained by the present invention.
- FIG. 14 is a view showing a mass spectrometry (mass) spectrum of the sulfated fucogalactan low molecular weight compound (D) obtained by the present invention.
- FIG. 15 1 H-NMR spectrum of sulfated low molecular weight fucogalactan (E) obtained by the present invention.
- FIG. 16 is a view showing a 13 C-NMR spectrum of a sulfated low molecular weight fucogalactan (E) obtained by the present invention.
- FIG. 17 is a diagram showing a mass spectrometry (mass) spectrum of the sulfated fucogalatatan reduced molecular weight product (E) obtained by the present invention.
- FIG. 3 is a diagram showing an NMR spectrum.
- FIG. 19 is a view showing a 13 C-DEPT-135 ° spectrum of a sulfated fucogalactan low molecular weight compound (F) obtained by the present invention.
- FIG. 20 is a view showing a mass spectrometry (mass) spectrum of a sulfated fucogalatan tan low molecular weight product (F) obtained by the present invention.
- FIG. 21 1 H-NMR spectrum of sulfated fucogalactan obtained by the present invention.
- FIG. 22 is a view showing 13 C-NMR spectrum of dihyfcogalactan sulfate obtained by the present invention.
- FIG. 23 is a view showing an infrared absorption spectrum of sulfated fucogalactan obtained by the present invention.
- Fig. 24 Mass spectrometry (mass) spectrum of 0.4 M sodium chloride eluted fraction of low molecular weight fucose sulfate-containing polysaccharide.
- Figure 25 1 H—NMR spectrum of a 0.4 M sodium chloride eluted fraction of a low molecular weight fucose sulfate-containing polysaccharide.
- Figure 2 6 is a diagram showing a 1 3 C-NMR scan Bae spectrum of 0 4 M chloride Natoriumu eluted fraction of the low molecular products of the sulfated-fucose-containing polysaccharide..
- Figure 27 1 H—NMR spectrum of a 0.6 M sodium chloride eluted fraction of a low molecular weight fucose sulfate-containing polysaccharide. Detailed description of the invention
- Seaweed belonging to brown algae contains a plurality of polysaccharides containing sifucose sulfate.
- sulfated fucan As the molecular species, sulfated fucan, sulfated fucodarcuronomannan, and many other molecular species have been reported.
- the sulfated fucogalatatan of the present invention mainly contains galactose and fucose as constituent sugars, and the molar ratio thereof is 1: 1 to 6: 1.
- the sulfated fucogalactan or G-fucoidan of the present invention will be described.
- a 2: 1 sulfated fucogalactan is exemplified.
- the average molecular weight of the sulfated polysaccharide is, for example, about 130,000 (the molecular weight distribution is about 100,000 to about 200,000) by HPLC gel filtration.
- the molecular weight, sugar composition, and sulfate group content of the sulfated fucogalactan vary depending on the harvesting period of the raw material of the sulfated fucogalactan, the method of drying the raw material, and the method of storing the raw material. Heating conditions, pH conditions, etc.
- the sulfated fucogalactan may be hydrolyzed by an acid. Therefore, the molecular weight, molecular weight distribution, sugar composition, or sulfate group content of the sulfated fucogalactan described in this specification is only one example, and the molecular weight, molecular weight distribution, and sugar composition depend on the extraction treatment conditions of the sulfated fucogalactan.
- the sulfate group content can be easily varied.
- the sulfated fucogalactan of the present invention is prepared using a polysaccharide mono-F-degrading enzyme, for example, the sulfated fucogalactan of the present invention having the above sugar composition and molecular weight is obtained. That is, depending on the conditions of the preparation method, it is possible to prepare diphthecogalactan sulfate having any molecular weight, molecular weight distribution, sugar composition, or sulfate group content.
- the main constituent saccharide of the sulfated fucogalatan tan of the present invention contains approximately 5 sulfate groups per hexasaccharide, but sulfate groups generally ester-linked to sugars are chemically unstable. Which is easily cleaved by acid, alkali or heat. For example, heat treatment under acidic or alkaline conditions will reduce the sulfuric acid content. That is, desulfation can be intentionally performed from the sulfated fucogalactan of the present invention. In addition, in desulfurization, if the type and concentration of acid and alkali, and the temperature and time during the heat treatment are adjusted, the amount of sulfate groups to be cut can be adjusted.
- the sulfated fucogalactan of the present invention may be derived from any brown alga if it is a sulfated fucogalactan having the above-mentioned characteristics or a sulfated fucogalactan that is reduced in molecular weight by the sulfated fucogalatatan degrading enzyme of the present invention. Is included.
- the main skeleton of the sulfated fucogalactan of the present invention is represented by the following general formula (XII).
- n is an integer of 1 or more, for example, in the range of 1 to 100, more preferably in the range of 1 to 500, is included in the dihifcogalactan sulfate of the present invention. It is.
- the sulfated fucogalatatan of the present invention has a structure in which the following general formula (XII) is continuously repeated and another structure intervenes, and discontinuously has the following general formula (XII). Any of those having a structure containing (XII) is included.
- R is H or S_ ⁇ 3 H
- the brown algae from which the diphtheria galactan sulfate of the present invention is derived are not particularly limited, but include, for example, gagome kelp, wakame, mako kelp, arame, kajime, kurome, resso nianidaresensu, giant kelp, durvillaea ) Can be prepared.
- fucoidan derived from Gagome kelp includes U-fucoidan, F-fucoidan, and G-fucoidan of the present invention.
- salts of fudogalactan sulfate of the present invention can be used, for example, salts of alkali metals such as sodium and potassium, salts of alkaline earth metals such as calcium and magnesium, zinc and the like. Or an ammonium salt of a transition metal.
- the low-molecular-weight fuifogalactan sulfate is an oligosaccharide obtained by allowing the sulfated fucogalactan degrading enzyme of the present invention to act on the sulfated fucogalactan of the present invention.
- Galactose or galactose The sulfated fucogalactan degrading enzyme of the present invention is a compound that acts on the sulfated fucogalactan of the present invention to lower the molecular weight of the sulfated fucogalactan to produce an oligosaccharide having sulfated galactose or galactose at the reducing end. .
- WO97 / 268896 discloses an end-fucose sulfate-containing polysaccharide degrading enzyme that degrades sulfated-fucose-containing polysaccharide mono-F, and the enzyme is a sulfated fucogalactan of the present invention. Do not disassemble. Further, the sulfated fucogalatatan degrading enzyme of the present invention comprises It is an enzyme that endogenously degrades the 31-6 bond and the 1-4 bond between D-sulfated galactose or galactose and D-sulfated galactose or galactose of oxidized fucogalactan.
- a sulfated fucogalactan of the present invention is purified from a brown alga-containing sulfated fucose-containing polysaccharide fraction.
- the method is simple. For example, in the production of a sulfated fucose-containing polysaccharide fraction, first, a water-soluble fraction extract of brown algae is obtained. In order to prevent the molecular weight of the sulfated fucose-containing polysaccharide from being reduced at that time, it is preferable to extract ⁇ 1 at 4 to 9 and at a temperature of 100 ° C or lower.
- Methods for removing alginic acid from the extract include a method using isoelectric focusing of alginic acid by acid treatment, a method of adding a salt that forms a precipitate with alginic acid, such as a calcium salt, and a method of decomposing with alginate-degrading enzyme. is there.
- ultrafiltration can be used to efficiently remove low molecules such as amino acids and mannitol.
- Activated carbon treatment is also effective for removing hydrophobic substances.
- the low molecular fraction is limited. It is good to remove by a filtration method and prepare the sulfated fucogalactan of the present invention.
- the sulfated fucogalactan obtained in this way may contain some sulfated fucosyl-containing polysaccharides other than sucrose fucogalatatan sulfate.
- the sulfated fucogalactan of the present invention can be isolated. According to this method, the amount of resin is smaller than the method of directly separating a mixture of sulfated fucose-containing polysaccharides using an anion exchange resin, and there is no mixing of the above two kinds of sulfated fucose-containing polysaccharides. Is significantly improved.
- the sulfated fucogalactan of the present invention obtained by the above-mentioned method is a substrate for measuring the activity when purifying the sulfated fucogalactanase of the present invention, or the sulfated fucogalactan of the present invention. It can also be used as a raw material when producing galactan oligosaccharides. Further, as a raw material at the time of production of oligosaccharides of sulfuric acid galactan sulfate, a mixture of the above-mentioned polysaccharides containing sulfuric acid sulfate may be used.
- the strain used for the production of the enzyme of the present invention is not particularly limited as long as it is a bacterium that produces an enzyme that reduces the molecular weight of the sulfated fucogalactan of the present invention.
- the flavobacterium described in W097 / 26896 can be used.
- NCBI Biotechnology Information
- the genus Flavobacterium described in this specification includes bacteria belonging to the genus Flavobacterium categorized from mycological properties and bacteria belonging to the order Sofagaga that are homologous in genetic classification. . Therefore, the case where the sulfated fucogalactan-degrading enzyme of the present invention is produced by culturing a bacterium belonging to the order of the Cytophaga is included in the method for producing a sulfated fucogalactan-degrading enzyme of the present invention.
- the culture medium of the strain used in the method for producing the sulfated fucogalactan-degrading enzyme of the present invention may be any medium as long as the strain used is metabolized and produces the sulfated fucogalactan-degrading enzyme of the present invention.
- Fucogalactan a mixture of sulfated fucose-containing polysaccharides, seaweed powder, alginic acid, fucose, galactose, glucose, mannitol, glycerol, saccharose, maltose, etc. can be used.
- As the nitrogen source peptone, yeast extract, meat extract, etc. are suitable.
- this strain grows very well in seawater or artificial seawater containing the above-mentioned nutrients.
- the production amount varies depending on the culturing conditions, but the culturing temperature is preferably 15 to 30 ° C, the pH of the medium is preferably 6 to 9, and the The production of the sulfated fucogalactan-decomposing enzyme of the present invention reaches the maximum after 72 hours of aeration and stirring culture.
- the culturing conditions are set so as to maximize the production of the sulfated fucogalactan-degrading enzyme of the present invention according to the strain used, the composition of the medium, and the like.
- the sulfated fucogalatatan degrading enzyme is present both in the cells and in the culture supernatant.
- Flavobacterium sp. SA-082 is cultured in a suitable medium, the cells are collected, and the cells are crushed by a commonly used cell disruption means, such as ultrasonic treatment.
- a cell extract is obtained.
- a purified enzyme preparation can be obtained from the extract by a commonly used purification method. For example, purified by salting out, ion exchange column chromatography, hydrophobic binding column chromatography, gel filtration, etc., and purified to substantially contain no other sulfated fucose-containing polysaccharide-degrading enzyme of the present invention. It is possible to obtain an enzyme capable of decomposing enzymes.
- a culture obtained by removing cells from the above-described culture solution. Since the present enzyme is present in a large amount in the culture supernatant, it can be purified by the same purification means as the intracellular enzyme.
- the physicochemical properties of the sulfated fucogalactan-decomposing enzyme of the present invention are as follows.
- FIG. 1 is a graph showing the relationship between the pH and the relative activity during the reaction of the present enzyme.
- the vertical axis indicates the relative activity (%), and the horizontal axis indicates the pH.
- FIG. 2 is a graph showing the relationship between the temperature and the relative activity during the reaction of the present enzyme.
- the vertical axis shows the relative activity (%), and the horizontal axis shows the temperature (° C.).
- the confirmation of the sulfated fucogalactan degrading enzyme of the present invention can be carried out, for example, by analyzing the degradation product obtained by reacting the enzyme with sulfated fucogalactan by HPLC and measuring the degree of reduction in molecular weight, or by reducing the resulting product.
- the measurement can be carried out by measuring the terminal by a conventional method.
- the activity can be measured either in the cell extract of the producing bacteria or in the enzyme solution after chromatographic purification.
- the low-molecular-weight product of sigma-fucogalactan sulfate of the present invention or a salt thereof is prepared by allowing the sulfated fucogalactan-decomposing enzyme of the present invention to act on the sulfated fucogalactan of the present invention or the sulfated fucogalactan-containing substance.
- the sulfated fucogalactan-containing material of the present invention include a partially purified product of the sulfated fucogalactan of the present invention, a sulfated fucose-containing polysaccharide fraction derived from brown algae, an aqueous solvent extract of brown algae, and brown algae algae.
- the body can be suitably used.
- the dissolution of the sulfated fucogalactan sulfate or the substance containing the sulfated fucogalactan sulfate of the present invention may be performed by a conventional method, and the solution containing the sulfated fucogalactan sulfate of the present invention or the sulfated fucogalatatan in a solution is contained.
- the concentration of the substance may be the highest dissolved concentration, but usually, it should be selected in consideration of the operation time and enzyme titer.
- water, a buffer or the like may be selected according to the purpose.
- Lysate p H is usually around neutral, and the enzyme reaction is usually carried out at around 30 ° C.
- the molecular weight of the low molecular weight compound can also be adjusted.
- the low molecular weight product of the present invention having a more uniform molecular weight distribution can be prepared by molecular weight fractionation of the low molecular weight product.
- a commonly used method can be applied. For example, a gel filtration method or a molecular weight fractionation membrane may be used.
- the low molecular weight compound may be further subjected to a purification operation such as an ion exchange resin treatment and an activated carbon treatment, if necessary, and may be subjected to a desalination treatment, an aseptic treatment, and a lyophilization treatment as necessary.
- a purification operation such as an ion exchange resin treatment and an activated carbon treatment, if necessary, and may be subjected to a desalination treatment, an aseptic treatment, and a lyophilization treatment as necessary.
- the low molecular weight product of the sulfated fucogalatatan of the present invention is not particularly limited.For example, disaccharides to hexasaccharides as low molecular weight products obtained by allowing the sulfated fucogalactan degrading enzyme of the present invention to act on the sulfated fucogalactan of the present invention. Is mentioned.
- the substitution position of the sulfate group present in the low molecular weight compound of the present invention varies depending on the preparation method, but if it is obtained by the action of the sulfated fucogalactan degrading enzyme of the present invention, the low molecular weight of the present invention may be changed. Included in child products.
- the chemical structure of the low molecular weight compound is represented by, for example, the following general formula (I)
- R is H or S_ ⁇ 3 H
- the low molecular weight compound of the present invention has a sulfate group in the molecule, and this group reacts with various base groups to form salts. Reduction of the molecular weight of these sulfated fucogaratatan of the present invention
- the product is stable in the salted state and is usually provided in the form of sodium and Z or potassium or Z and a salt such as calcium.
- a cation exchange resin such as Dowex 50 W (manufactured by Dow Chemical Company)
- salts of these substances can be converted into free low molecular weight products of the sulfated fucogalactan of the present invention.
- these can be further exchanged with various desired salts by performing known and conventional salt exchange, if necessary.
- salts of the low-molecular-weight sulfated fucogalactan of the present invention for example, salts of alkali metals such as sodium and potassium, and salts of alkaline earth metals such as calcium and magnesium. And salts of transition metals such as zinc, and ammonium salts.
- the sulfated fucogalactan degrading enzyme of the present invention is used, only the sulfated fucogalactan of the present invention contained in any sulfated fucose-containing polysaccharide fraction can be reduced in molecular weight.
- the combination it is possible to selectively remove the sulfated fucogalatatan of the present invention.
- the sulfated fucan fraction has various biological activities such as an anticoagulant activity, a cancer metastasis inhibitory activity, and a virus infection inhibitory activity. So far, sulfated fucan and other polysaccharides have been contained in the sulfated efifucane fraction obtained from brown algae.
- sulfated fucogalactan-degrading enzyme of the present invention sulfated fucogalactan can be removed from the sulfated fucan fraction, and as a result, high-purity sulfated fucan can be obtained.
- sulfated fucodalc mouth nomannan has an apoptosis-inducing effect on cancer cells. Therefore, by utilizing the sulfated fucogalactanase-decomposing enzyme of the present invention, the sulfated fucogalatatan of the present invention, which is contaminated with the sulfated fucodalchronomannan obtained from brown algae, can be easily removed. A high-purity sulfated fucoglucuronomannan can be easily obtained.
- a solution in which the sulfated fucogalactan-containing substance of the present invention is dissolved in an aqueous solvent is prepared.
- the dissolution of the sulfated-fucogalactan-containing material of the present invention may be carried out by a usual method, and the concentration of the sulfated fucogalactan-containing material of the present invention in the dissolution solution may be the highest dissolved concentration.
- the selection should be made in consideration of the workability and enzyme titer.
- the sulfated fucogalactan solution of the present invention may be selected from water, a buffer, and the like depending on the purpose.
- the pH of the solution is usually preferably around neutral.
- the sulfated fucogalactan-degrading enzyme of the present invention or an immobilized product of the enzyme, or both are added to the sulfated fucogalactan-containing solution of the present invention and reacted to reduce the molecular weight of the sulfated fucogalactan of the present invention.
- the enzymatic reaction is usually carried out at around 30 ° C., and the amount of the enzyme and the reaction time may be appropriately adjusted according to the molecular weight fractionation ability in the next step.
- a target product from which the low-molecular-weight sulfated fucogalatatan of the present invention has been easily removed can be prepared.
- a commonly used method can be applied. For example, a gel filtration method or an ultrafiltration method using a molecular weight fractionation membrane may be used.
- the sulfated fucogalactan degrading enzyme of the present invention acts on the sulfated fucogalactan of the present invention, it can be used for structural analysis of the sulfated fucogalactan of the present invention.
- the sulfated fucogalactan-decomposing enzyme of the present invention is allowed to act on the sulfated fucogalactan of the present invention, a low molecular weight compound having a chemical structure represented by any one of the general formulas (I) to (IV) is obtained.
- the use of the sulfated fucogalactan-decomposing enzyme of the present invention enables the sulfated fucogalactan component of the present invention to be selectively removed from the sulfated fucose-containing fucose-containing polysaccharide containing the sulfated fucogalactan of the present invention.
- the high-purity sulfated fucan or sulfated fucodarcuronomannan after removing the sulfated fucogalactan component of the present invention can be suitably used as a raw material of a pharmaceutical.
- the sulfated fucogalactan-degrading enzyme of the present invention is a sulfated-fucose-containing polysaccharide mono-F-degrading enzyme described in W097Z2686 and / or a fucose described in WO97 / 26689.
- a sulfated saccharide represented by the following general formula (XIV) is used as an essential component of the constituent saccharide, and a sulfated polysaccharide having a repeating structure thereof can be obtained.
- n is an integer of 1 or more, and is, for example, in the range of 1 to 100, 000, more preferably 1 to 50,000. Range of things can be obtained
- R is H or OS 0 3 H
- the sulfated polysaccharide contains fucose as a constituent sugar.
- the average molecular weight is about 200,000 (the molecular weight distribution is about 10,000 to about 100,000). It is. Further, for example, when the processing conditions at the time of extraction are pH 6 to 8 and 25 ° C for 24 hours, the average molecular weight is about 1,300,000 (the molecular weight distribution is about 100,000 to About 2,000,000). Thus, the average molecular weight and the molecular weight distribution differ depending on the extraction conditions.
- the sulfated polysaccharide obtained under any of the extraction conditions is reduced to a molecular weight by the above-mentioned sulfated-fucose-containing polysaccharide-1F-degrading enzyme.
- the molecular weight and sulfate group content of the sulfated polysaccharide vary depending on the harvesting period of the raw material of the sulfated polysaccharide, the method of drying the raw material, and the method of storing the raw material, and also depend on the heating conditions during extraction, pH conditions, and the like. different. For example, it may be hydrolyzed by an acid.
- the molecular weight, molecular weight distribution, or sulfate group content of the sulfated polysaccharide described in this specification is only one example, and the molecular weight, molecular weight distribution, or sulfuric acid content of the sulfated polysaccharide depends on the extraction treatment conditions of the sulfated polysaccharide.
- the group content can easily be varied. That is, the above-mentioned sulfated polysaccharide having an arbitrary molecular weight, molecular weight distribution or sulfate group content can be prepared depending on the conditions of the preparation method.
- the main constituent sugars of the above sulfated polysaccharides contain about 12 residues of sulfate groups per 7 sugars, but sulfate groups generally ester-linked to sugars are chemically unstable. And is easily cleaved by acid, alkali or heat. For example, heat treatment under acidic or alkaline conditions reduces the sulfuric acid content. It is less. That is, desulfation can be intentionally performed from the sulfated polysaccharide. Also, the amount of sulfate groups to be cut can be adjusted by adjusting the types and concentrations of acids and alkalis and the temperature and time during the heat treatment during desulfation.
- a novel sulfated saccharide can be obtained by using a combination of the sulfated fucogalactan degrading enzyme, the sulfated-fucose-containing polysaccharide-F degrading enzyme, and the sulfated-fucose-containing polysaccharide-U degrading enzyme.
- a combination of the above three types of degrading enzymes can be used to classify sulfated saccharides different from conventional ones.
- Fucose sulfate-containing polysaccharide-a sulfated saccharide fraction that is not degraded by an F-degrading enzyme or a fucose-sulfuric acid-containing polysaccharide-U degrading enzyme and is degraded by a sulfated fucogalactan-degrading enzyme (the sulfated fucogalactan of the present invention);
- sulfated saccharide fractions can be obtained for the first time by combining the fucogalactanase of the present invention with the sulfated-fucose-containing polysaccharide-1F-degrading enzyme or the sulfated-fucose-containing polysaccharide-1U-degrading enzyme.
- the sulfated fucogalatatan or a salt thereof of the present invention has a growth factor production-inducing activity, particularly an HGF (hepatocyte growth factor) production-inducing activity.
- HGF hepatocyte growth factor
- HGF promotes proliferation of not only dry cells but also many epithelial cells such as bile duct epithelial cells, renal tubular epithelial cells, and gastric mucosal cells.
- HGF is a multifunctional active substance that exhibits extremely diverse physiological activities, such as enhancing epithelial cell motility, vascularization, and inducing morphogenesis as seen in epithelial cell lumen formation. In other words, it promotes the growth of epithelial cells in various organs when repairing damage to the organs, and induces morphogenesis such as increased motility and angiogenesis.
- HGF has a hepatocyte growth-promoting action, a protein synthesis-promoting action, a cholestasis-improving action, and a drug-preventing action on kidney damage. For these reasons, it is expected to be used as a therapeutic agent for severe hepatitis, cirrhosis and intrahepatic cholestasis.
- HGF mRNA is also synthesized in the brain, kidney, lung, etc., and is a mesodermal cell growth factor that has proliferative activity on hepatic parenchymal cells, renal tubular cells, epidermal cells, and the like. Therefore, the sulfated fucogalactan of the present invention or a salt thereof induces the production of hepatocyte growth factor, and thereby is used as a therapeutic agent for hepatitis, severe hepatitis, cirrhosis and intrahepatic cholestasis, chronic nephritis, pneumonia, wound, or Useful as a component of a prophylactic agent.
- the sulfated fucogalactan or a salt thereof of the present invention can be used as an active ingredient of cosmetics by its HGF production inducing action, and is useful as, for example, an HGF production inducing cosmetic, and has an HGF production inducing action.
- the present invention can provide a biochemical cosmetic having the same.
- the cosmetic for inducing growth factor production for example, the cosmetic for inducing HGF production, containing the sulfated fucogalactan or a salt thereof of the present invention can be produced according to a conventional method, for example, lotions, emulsions, creams, Examples include packs, bath preparations, facial cleansers, bath cleaners, hair preparations, hair restorers or hair cleansers.
- the sulfated fucogalactan of the present invention, a low molecular weight compound of the sulfated fucogalactan, or a salt thereof can be used as an antigen.
- Antibodies are produced by a conventional method.
- the antibody of the present invention may be prepared by using a salt of fifcogalactan sulfate of the present invention, a low-molecular-weight product of the sulfated fucogalatan, or a salt thereof together with an adjuvant, such as a heron. By immunizing the product, a polyclonal antibody can be prepared.
- Monoclonal antibodies can also be prepared by fusing melanoma cells with antibody-producing B cells obtained by immunizing with an antigen, selecting a hybridoma that produces the desired antibody, and culturing the cells. it can. These antibodies can be used for purification of the sulfated fucogalactan of the present invention, a low molecular weight product of the sulfated fucogalactan, or a salt thereof. Further, it can be used for identification of the sulfated fucogalatatan of the present invention in seaweed.
- the content of the sulfated fucogalactan of the present invention in the seaweed extract can be easily measured by using the antibody that recognizes the sulfated fucogalactan of the present invention, and the high-content extract can be efficiently prepared.
- the antibody recognizing the sulfated fucogalatan, the low molecular weight product of the sulfated fucogalatan, or the salt thereof according to the present invention includes the sulfated fucoragaltan, the low molecular weight product of the sulfated fucogalatan, or the low molecular weight product thereof. It is useful for analyzing the mechanism of salt inhibition of fertilization, the mechanism of viral infection inhibition, and the metabolism in vivo.
- the low molecular weight product, ie, oligosaccharide, obtained by allowing the sulfated fucogalactan degrading enzyme of the present invention to act on the sulfated fucogalactan of the present invention or a salt thereof can be used as a sugar chain engineering reagent.
- a sugar chain engineering reagent for example, if pyridyl- (2) -amination (PA conversion) is carried out by the method described in Japanese Patent Publication No. 5-6510-8 to prepare a PA compound of the low-molecular-weight compound, it can be extremely used as a reagent for sugar chain engineering. Useful substances can be provided.
- PA conversion pyridyl- (2) -amination
- Sulfated fucogalactan was prepared by the following steps.
- the amount of fucose was quantified as described in (1948).
- the obtained dried preparation of sulfated fucogalatatan was dissolved in 1N hydrochloric acid at a concentration of 0.5%, treated at 110 ° C for 2 hours, and hydrolyzed to a constituent monosaccharide.
- the reducing end of the monosaccharide obtained by hydrolysis using Glycotta Tug (Takara Shuzo Co., Ltd.) and Glycotta Tug Reagent Kit (Takara Shuzo Co., Ltd.) is subjected to pyridyl (2) -amination (PA conversion).
- the ratio of constituent sugars was examined by HP LC.
- the conditions of HP are as follows.
- the obtained sulfated fucogalactan contained galactose and fucose as constituent sugars, and the molar ratio was about 2: 1. Peronic acid and other neutral sugars were not substantially contained. The molar ratio of fucose to sulfate groups was about 1: 2.
- the activity of the sulfated fucogalactanase of the present invention was measured using the sulfated fucogalactan fraction obtained in (2) in the following manner.
- One unit of the enzyme is the amount of the enzyme that cleaves the galactosyl bond of the 1 ⁇ mole-sulfated fucogalactan fraction in the above reaction system per minute.
- M average molecular weight of reaction product (MG / M) — 1: Number of one molecule of sulfated fucogalactan cleaved by the enzyme
- HP LC conditions were as follows.
- A-0082 (FERM BP-5402) in artificial seawater (manufactured by Jamarin Laboratories) pH 7.5 containing 0.1% of gnorecose, 1.0% of peptone, and 0.05% of yeast extract.
- the medium was inoculated into a sterilized medium at 20 ° C for 20 minutes, and cultured at 24 ° C for 23 hours to obtain a seed culture solution.
- sulfated fucose-containing polysaccharide fraction derived from Gagome kelp prepared by the method of Example 3 (1) below, 2.0% of peptone, 0.01% of yeast extract, and an antifoaming agent (KM70, 20 liters of a medium consisting of artificial seawater (pH 7.5) containing 0.01% was sterilized at 120 C for 20 minutes in a 30-liter jar armmenter. After cooling, inoculate 600 ml of the above seed culture and incubate at 24 ° C for 23 hours at 10 l / min and 12 min / min. Culture was performed under the conditions of a stirring speed of 5 rotations. After completion of the culture, the culture was centrifuged to obtain cells.
- the obtained cells are suspended in 1,200 ml of 1 OmM Tris-HCl buffer (pH 8.0) containing 0.4 M sodium chloride, sonicated, and then centrifuged to extract the cells. A liquid was obtained.
- the obtained bacterial cell extract was sufficiently dialyzed against the same buffer and centrifuged to obtain a supernatant. Ammonium sulfate was added to the obtained supernatant to a final concentration of 90% saturation, and the resulting precipitate was collected by centrifugation.
- the resulting precipitate was dissolved in 10 mM Tris-HCl buffer (pH 8.0) containing 15 Om 1 of 5 OmM sodium chloride, dialyzed sufficiently with the same buffer, and centrifuged.
- the resulting supernatant is applied to a 50 OmL column of DEAE-Sepharose FF (Amersham Pharmacia) equilibrated with the same buffer solution, washed with the same buffer, and then subjected to a concentration of 50 mM to 600 mM sodium chloride. The active fraction was collected by elution with a gradient.
- DEAE-Sepharose FF Amersham Pharmacia
- the obtained active fraction was sufficiently dialyzed against 10 mM Tris-HCl buffer (pH 8.0) containing 0.1 M sodium chloride, and 10 OmL of DEAE equilibrated with the same buffer. After washing with the same buffer, the column was eluted with a concentration gradient of 0.1M to 0.4M sodium chloride, and the active fraction was collected. The obtained active fraction was added with sodium chloride to a concentration of 4M, and the mixture was equilibrated with a 10 mM Tris-hydrochloride buffer (pH 8.0) containing 4M sodium chloride.
- reaction solution was concentrated to 8 Om1 using an evaporator, and subjected to molecular weight fractionation using a column (4 ⁇ 9 Ocm) of Cell mouth Fine GCL-1000 (manufactured by Chisso). Fractions having a molecular weight of 15,000 or less were collected and used as a sulfated fucogalactan enzyme digest fraction.
- a polysaccharide fraction containing sulfated fucose was prepared from Gagome kelp. That is, 2 kg of commercially available dried gagome kelp is a cutter mill equipped with a screen with a hole diameter of lmm.
- the resulting supernatant was concentrated to 4 liters with an ultrafilter equipped with a hollow fiber with a molecular weight cut off of 100,000, and then insoluble substances were removed by centrifugation, followed by standing at 5 ° C for 24 hours.
- the resulting precipitate was removed by centrifugation, and the obtained supernatant was exchanged with an ultrafilter to give a 10 OmM sodium chloride solution.
- the pH was adjusted to 2.0 with hydrochloric acid, and the resulting precipitate was removed by centrifugation.
- the pH of the resulting supernatant was adjusted to 8.0 with sodium hydroxide, concentrated to 4 liters, and then exchanged with 2 OmM sodium chloride by an ultrafilter.
- Flavopacterium sp. S A-0082 (FERM BP-5402) was prepared by the method of Example 3 (1), and contained 0.2% of a polysaccharide fraction containing sulphicose sulfate derived from gagome kelp. Artificial seawater (p. 1.0%, yeast extract 0.01%)
- the medium consisting of H7.5 was placed in a 50 Om1 Erlenmeyer flask, inoculated into a sterilized medium at 120 ° C for 20 minutes, and cultured with shaking at 24 ° C for 23 hours. After completion of the culture, the culture solution was centrifuged to obtain bacterial cells and culture solution supernatant.
- the obtained cells were washed with 1 OmM Tris containing 5 ml of 0.4 M sodium chloride.
- the cells were suspended in hydrochloric acid buffer (pH 8.0), sonicated, and centrifuged to obtain a cell extract.
- the culture supernatant was 2 mU / ml of the culture medium
- the cell extract was 2 mU / ml of the culture medium.
- An activity of 2 mU was detected.
- the sulfated fucogalactan-decomposing enzyme of the present invention was contained in the cells of the genus Flavobacterium and in approximately the same amount outside the cells.
- the above-mentioned fraction also contained about 10% of a component degraded by the sulfated fucogalactan-decomposing enzyme, that is, about 10% of the present invention. Therefore, this fraction was desalted with an ultrafilter equipped with a holofiber having a molecular weight cutoff of 100,000, and further dissolved in a 20 mM imidazole monohydrochloride buffer (pH 8.0) containing 200 mM sodium chloride. Replaced. Thereto, 60 OmU of the sulfated fucogalatatan degrading enzyme of the present invention was added, and the mixture was reacted at 25 ° C for 3 days, followed by ultrafiltration, and the amount of sugar contained in the filtrate was determined by the sulfuric acid method.
- Example 3 70 g of the sulfated fucose-containing polysaccharide fraction derived from Gagome kelp obtained in Example 3 was added to 3 After dissolving in 20 mM imidazole-hydrochloric acid buffer (pH 7.5) containing 0 OmM sodium salt, 2 OmM sodium chloride, and 10% ethanol, a holofiber with 100,000 exclusion molecular weight was attached. Ultrafiltration was performed using an ultrafiltration machine that had been removed to thoroughly remove substances that could be filtered. The buffer added at the time of ultrafiltration had the same composition as the buffer used for dissolution.
- an Alteromonas sp. 3 ⁇ -1009 strain (? £ 1 1 ⁇ 8? -5747) was cultured in the ultrafiltration solution according to the method described in WO 97/26896, and the culture strength ⁇ 25 U of the obtained sulfated-fucose-containing polysaccharide mono-F-degrading enzyme was added; The reaction was performed at C for 3 days.
- the above reaction solution is ultrafiltered with an ultrafiltration machine equipped with a hollow fiber of 100,000 excluded molecular weight, and the substance degraded by the fucose sulfate-containing polysaccharide mono-F-degrading enzyme, that is, the depolymerized fucoidan is obtained. Removed thoroughly.
- the buffer added at the time of ultrafiltration had the same composition as the buffer used in the above reaction solution.
- flavobacterium sp. SA-0082 strain (FERM BP-5402) was cultured in the ultrafiltration solution according to the method described in W097Z26896, and the sulfated-fucose-containing polysaccharide-U degraded from the culture was cultured. 20 U of the enzyme was added and reacted at 25 ° C. for 5 days.
- the above reaction solution was ultrafiltered with an ultrafiltration machine equipped with a hollow fiber with a rejection molecular weight of 100,000, and a substance reduced in molecular weight by the above-mentioned sulfated-fucose-containing polysaccharide-1U-degrading enzyme, that is, sulfated fucodarcuronomannan Low molecular weight compounds were thoroughly removed.
- water was added to the mixture, and finally it was replaced with a 10 mM Tris-HCl buffer (pH 8) containing 20 OmM sodium chloride.
- the sulfated fucogalactan-degrading enzyme described in Example 2 (1) was added to the ultrafiltration solution in a 2U-added mash, and reacted at 25 ° C. for 5 days.
- the reaction solution was divided into two equal parts, and one was subjected to ultrafiltration using an ultrafiltration machine equipped with a holofiber with a molecular weight of 100,000, and a substance reduced in molecular weight by the sulfated fucogalactan degrading enzyme, that is, The low molecular weight product of sulfated fucogalatatan was thoroughly ultrafiltered.
- 1 OmM Tris-monohydrochloride buffer (pH 8) containing 5 OmM sodium chloride was added.
- the filtrate obtained in this manner was used as a sulfated fucogalatatan enzyme digest (i).
- Example 5 The sulfuric acid described in Example 2 (1) was The duck fucogaratatan-degrading enzyme was added to 55 OmU-added casket and allowed to react at 25 ° C. for 7 days to confirm the progress of the molecular reduction.
- the reaction solution was subjected to ultrafiltration using an ultrafiltration machine equipped with a hollow fiber having an exclusion molecular weight of 100,000, and thorough ultrafiltration was performed on low molecular weight products of sulfated fucogalactan.
- 1 OmM tris-hydrochloric acid buffer (pH 8) containing 5 OmM sodium chloride was added thereto.
- the filtrate obtained in this manner was designated as enzyme digest (ii).
- the enzyme digest (i) of sulfated fucogalatatan obtained in Example 5 (1) was concentrated to 50 Om1 by an evaporator, desalted by an electrodialyzer, and then 10 mM of 10 mM containing 1 OmM sodium chloride in advance. Apply 1 liter of DEAE-Cell Mouth Fine A-800 (manufactured by Chisso) column equilibrated with imidazole-hydrochloric acid buffer (pH 8), wash with the same buffer, and wash with 1 OmM to 90 OmM chloride. Eluted with sodium gradient. The eluted fraction was collected in 62 ml portions, and the sugar content of each was measured by the phenol monosulfuric acid method.
- the OmM elution fraction (i) was desalted with an electrodialyzer, sodium chloride was dissolved to 5 OmM, and 10 mM imidazole monohydrochloride buffer (pH 8 ) was applied to a column of 100 ml of DEAE-Cell mouth Fine A-800 (manufactured by Chisso) equilibrated with) and washed with the same buffer.
- Elution was carried out with a gradient of sodium chloride from 5 to 20 OmM.
- the eluted fraction was fractionated in 10 ml portions, and the sugar content of each fraction was measured by the phenol monosulfuric acid method. Since the fraction eluted with sodium chloride at around 55 mM to 75 mM formed a peak of the sugar content, the fraction eluted with sodium chloride at around 60 mM was collected. This fraction was concentrated to 2 ml by speed knock (manufactured by Savant Instruments Inc .; SAVANT Instruments Inc.), and was previously equilibrated with 10% ethanol. And eluted with the same buffer. The eluted fractions were collected in 2 ml portions, and their sugar contents were measured by the phenol monosulfuric acid method. Collect the fractions whose sugar content forms a peak, (A).
- OmM elution fraction (i) after desalting with an electrodialyzer, sodium chloride was dissolved to 10 OmM, and 10 mM imidazole-hydrochloride containing 10 OmM sodium chloride beforehand was dissolved. The solution is applied to a column of 10 Oml of DEAE-Cell mouth Fine A-800 (manufactured by Chisso) equilibrated with a buffer solution (pH 8), washed with the same buffer solution, and washed with 10 OmM to 350 mM sodium chloride. Eluted by gradient. The eluted fraction was fractionated by 1 Om1 and each sugar content was measured by the phenol-sulfuric acid method.
- Fractions eluted with sodium chloride at around 16 OmM were collected, concentrated to 2 ml with a Speed Vac (manufactured by Savant Instruments Inc.), and then equilibrated with 10% ethanol beforehand.
- the sample was applied to a column of Cell Open Fine GCL-25 (manufactured by Chisso) and eluted with the same buffer.
- the eluted fraction was fractionated by 2 ml, and the sugar content of each fraction was measured by the phenolic sulfuric acid method. Collect the fractions whose sugar content forms a peak,
- Example 5 The sulfated fucogalactan enzyme digest (2) described in (2) was concentrated to 50 Om1 using an evaporator, and then desalted using an electrodialyzer, and 10 mM imidazole containing 1 OmM sodium chloride was previously added. Apply a 1 liter column of DEAE-Cell mouth Fine A-800 (manufactured by Chisso) equilibrated with hydrochloric acid buffer (pH 8), wash with the same buffer, and wash 10 mM to 900 mM sodium chloride. The gradient was eluted. The eluted fraction was collected in 6 lm 1 portions, and the sugar content of each fraction was measured by the phenol monosulfuric acid method.
- the fractions eluted with sodium chloride at around 130 mM, around 220 mM and around 27 OmM formed a peak of the sugar content, so that they were collected, and the 13 OmM elution fraction (ii) and the 22 OmM elution fraction (Ii) and 27 OmM elution fraction (ii).
- the 130 mM elution fraction (ii) was desalted with an electrodialyzer, sodium chloride was dissolved to 20 mM, and 10 mM imidazole-hydrochloric acid buffer (pH 8) containing 2 OmM salt solution was previously added.
- 10 mM imidazole-hydrochloric acid buffer (pH 8) containing 2 OmM salt solution was previously added.
- Fractions eluted with sodium chloride from 5 OmM to 7 OmM were collected, concentrated to 3 Oml with an evaporator, and then equilibrated with 10% ethanol beforehand. And eluted with the same buffer. The eluted fraction was fractionated by 1 Oml, and the sugar content of each fraction was measured by the phenol-monosulfuric acid method. Collect the fractions whose sugar content forms a peak,
- the sample was applied to a 200 ml column of Fine GCL-25 (manufactured by Chisso Corporation), which had been flattened with 10% ethanol, and eluted with the same solution.
- the eluted fraction was fractionated by 2 ml, and the sugar content of each fraction was measured by the phenol-sulfuric acid method.
- Mass spectrometry of the fraction with a peak sugar content revealed that the same substance as in (A) was present in the first half, but the same substance as in (A) was present in the second half. Since it was not included, the second half fraction was collected and designated as (C).
- the above 220 mM elution fraction (ii) was added with water so as to have the same conductivity as that of 10 mM imidazole-hydrochloric acid buffer containing 100 mM sodium chloride, and 1.0 OmM was added in advance.
- a column of 20 Om 1 DEAE-Cell mouth Fine A-800 manufactured by Chisso Corporation
- 1 OmM imidazo monohydrochloric acid buffer solution (pH 8) containing sodium chloride washed with the same buffer solution, From 10 OmM
- the above reaction solution is subjected to ultrafiltration using an ultrafiltration machine equipped with a hollow fiber having a rejection molecular weight of 100,000, and the above fucose sulfate-containing polysaccharide-substance degraded by F-degrading enzyme, that is, low fucoidan. Molecular compounds were thoroughly removed.
- the buffer added at the time of ultrafiltration had the same composition as the buffer used for dissolution.
- Example 5 1 U of the sulfated-fucose-containing polysaccharide monolytic enzyme used in Example 5 (1) was added to the ultrafiltration solution, and the mixture was reacted at 25 ° C. for 5 days.
- the above reaction solution is ultrafiltered with an ultrafiltration machine equipped with a hollow fiber having a rejection molecular weight of 100,000, and the substance reduced in molecular weight by the above-mentioned sulfated-fucose-containing polysaccharide-u-degrading enzyme, that is, sulfated
- the low molecular weight compound of fucoglucuronomannan was thoroughly removed.
- 10 mM Tris-hydrochloric acid buffer ( ⁇ 8) containing 20 OmM sodium chloride and 10% ethanol was added.
- Example 2 (1) the sulfated fucogalatatan degrading enzyme described in Example 2 (1) was added to the inner solution of the ultrafiltration.
- 60 OmU was added and reacted at 25 ° C. for 5 days. Exclude the reaction solution by ultrafiltration using an ultrafiltration machine equipped with a 100,000 molecular weight holofiber, and thoroughly remove the substances degraded by the sulfated fucogalatatan degrading enzyme, that is, the depolymerized sulfated fucogalatatan. And ultrafiltered. During ultrafiltration, 10% ethanol containing 2 OmM sodium chloride was added. The filtrate obtained in this manner was used as a sulfated fucogalatatan enzyme digest (iiii).
- the enzyme digest of fucogaratatan sulfate (iii) obtained in Example 6 (1) was desalted with an electrodialyzer, concentrated to 5 Om1 by an evaporator, and then concentrated to 50 m1 in advance.
- the column was loaded on a 10 Om 1 DEAE-Cell Mouth Fine A-800 (manufactured by Chisso) column equilibrated with ammonium acetate (pH 5.5), washed with the same buffer, and washed with 50 mM to 4 M ammonium acetate. Eluted with a gradient.
- the eluted fraction was fractionated by 1 Oml, and the sugar content of each fraction was measured by the phenol-sulfuric acid method.
- the fraction was desalted with an electrodialyzer, made to have the same conductivity as a 5 OmM ammonium acetate solution, and 10 Om 1 DEAE-cell port previously equilibrated with 5 OmM ammonium acetate (pH 5.5). Run on a column of Fine A-800 (manufactured by Chisso), wash with the same buffer, wash with 100 mM ammonium acetate (pH 5.5), and gradient from 10 OmM to 80 OmM ammonium acetate. And eluted. The eluted fraction was fractionated by 1 Om 1 and the sugar content of each fraction was measured by the phenol monosulfuric acid method. Fractions eluted with ammonium acetate in the range of 44 to 53 OmM were collected.
- the fraction was desalted with an electrodialyzer, made to have the same electrical conductivity as a 20 OmM ammonium acetate solution, and 10 Om 1 DEAE-cell port which had been preliminarily equilibrated with 20 OmM ammonium acetate (pH 5.5).
- the column was eluted with a gradient of 20 to 70 OmM ammonium acetate.
- the eluted fraction was fractionated by 1 Om 1 and the sugar content of each fraction was measured by the phenol monosulfuric acid method. Fractions eluted with about 420 mM to 470 mM ammonium acetate were collected.
- the fraction was analyzed by mass spectrometry and nuclear magnetic resonance spectroscopy (NMR), and was estimated to be the same substance as (B) described in Example 5 (3).
- the mass spectrometry was performed using an AP I-II I mass spectrometer (manufactured by Pachinkin Elma-Sykes).
- NMR analysis was performed using a nuclear magnetic resonance apparatus JMN-A500 (manufactured by JEOL Ltd.).
- the reaction solution was desalted with an electrodialyzer, made to have the same electrical conductivity as a 5 OmM ammonium acetate solution, and preliminarily equilibrated with 5 OmM ammonium acetate (pH 5.5).
- the solution was applied to a column of Fine A-800 (manufactured by Chisso), washed with the same buffer, and eluted with a gradient of 10 OmM to 1 M ammonium acetate.
- the eluted fraction was collected in 10 ml portions, and the sugar content of each was measured by the phenol monosulfuric acid method.
- the six fractions (A), (B), (C), (D), (E), and (F) obtained in Examples 5 and 6 were desalted by an electrodialysis device, and then lyophilized.
- the sugar content and the mass were analyzed.
- mass spectrometry an AP I-III mass spectrometer (manufactured by Perkin-Elma Syechs) was used.
- NMR analysis a J NM-o: 500 type nuclear magnetic resonance apparatus (manufactured by JEOL Ltd.) was used.
- the analysis sample was subjected to structural analysis after replacement with heavy water according to a standard method.
- the binding mode of the constituent sugars was determined using the HMBC method, which is a 1 H-detection heteronuclear detection method.
- the DQF-COSY method and the HOHAHA method were used for assignment of 1 H-NMR, and the HSQC method was used for assignment of 13 C-NMR.
- FIG. 3 is a diagram showing a 1 H-NMR spectrum of the low molecular weight fucogalactan sulfate (A) of the present invention
- FIG. 4 is a diagram showing 13 C-NMR spectrum of the low molecular weight fucogalactan sulfate (A) of the present invention.
- FIG. 5 is a diagram showing a mass spectrum of the sulfated fucogalatatan reduced molecular weight product (A) of the present invention.
- the vertical axis indicates the signal intensity
- the horizontal axis indicates the chemical shift value (ppm).
- the vertical axis represents the relative intensity.
- Table 1 shows the chemical shift values of each carbon at the time of 13 C-NMR analysis. Position of carbon 13 C—NMR chemical shift value (p pm)
- FIG. 6 shows the 1 H-NMR spectrum of the sulfated fucogalactan low molecular weight compound (B) of the present invention
- FIG. 7 shows the 13 C-NMR spectrum
- Figure 8 shows the mass spectrum. That is, FIG. 6 is a diagram showing a 1 H-NMR spectrum of the sulfated fucogalactan low molecular weight compound (B) of the present invention, and FIG. 7 is a 13 C-NMR of the sulfated fucogalactan low molecular weight compound (B) of the present invention.
- FIG. 8 is a diagram showing a spectrum, and FIG.
- FIGS. 6 and 7 are diagram showing a spectrum of a low molecular weight product of diphtheria galatatan sulfate (B) of the present invention.
- the vertical axis represents the signal intensity
- the horizontal axis represents the chemical shift value (ppm).
- the vertical axis represents the relative intensity.
- Table 2 shows the chemical shift values of each carbon at the time of 13 C-NMR analysis.
- FIG. 9 is a diagram showing a 1 H-NMR spectrum of the sulfated fucogalatan tan low molecular weight product (C) of the present invention
- FIG. 10 is a 13 C-NMR of the sulfated fucogalactan low molecular weight product (C) of the present invention.
- FIG. 11 is a view showing a spectrum
- FIG. 9 is a diagram showing a 1 H-NMR spectrum of the sulfated fucogalatan tan low molecular weight product (C) of the present invention
- FIG. 10 is a 13 C-NMR of the sulfated fucogalactan low molecular weight product (C) of the present invention.
- FIG. 11 is a view showing a spectrum
- FIG. 11 is a view showing a spectrum
- FIG. 11 is a view showing a mass spectrum of the sulfated fucogalactan low molecular weight compound (C) of the present invention.
- the vertical axis indicates the signal intensity
- the horizontal axis indicates the chemical shift value (ppm).
- the vertical axis represents the relative intensity (%)
- the horizontal axis represents the m / Z value.
- G1-6-H 3.82 (1H, m, G1-5-H), 3.80 (1H, m, G16-H) 3.63 (2H, m, G2-6 -H), 3.62 (1H, m, G2-5-H), 3.55 (1H, m, G2—2—H), 3.50 (1H, m, G1-2-H) )
- FIG. 12 shows the 1 H-NMR spectrum of the sulfated fucogalactan compound (D) of the present invention
- FIG. 1 shows the 13 C-NMR spectrum thereof
- Fig. 14 shows the mass spectrum in Fig. 3. That is, FIG. 12 is a diagram showing the 1 H-NMR spectrum of the sulfated fucogalactan low molecular weight product (D) of the present invention, and FIG. 13 is 13 C—N of the sulfated fucogalactan low molecular weight product (D) of the present invention.
- FIG. 14 is a view showing an MR spectrum
- FIG. 14 is a view showing an MR spectrum
- FIG. 14 is a view showing a mass spectrum of the sulfated fucogalatan tan low molecular weight compound (D) of the present invention.
- the vertical axis represents the signal intensity
- the horizontal axis represents the chemical shift value (ppm).
- the vertical axis represents the relative intensity (%)
- the horizontal axis represents the mZZ value.
- FIG. 15 shows the 1 H-NMR spectrum
- FIG. 16 shows the 13 C-NMR spectrum of the low molecular weight sulfated fucogalactan (E) of the present invention.
- the mass spectrum is shown in FIG. That is, FIG. 15 is a diagram showing the 1 H-NMR spectrum of the sulfated fucogalactan low molecular weight product (E) of the present invention, and FIG. 16 is a diagram showing 13 C— of the sulfated fucogalactan low molecular weight product (E) of the present invention.
- FIG. 17 is a diagram showing an NMR spectrum
- FIG. 17 is a diagram showing an NMR spectrum
- FIG. 17 is a diagram showing a mass spectrum of the sulfated fucogalactan low molecular weight compound (E) of the present invention.
- the vertical axis indicates the signal intensity
- the horizontal axis indicates the chemical shift value (ppm).
- the vertical axis represents the relative intensity (%)
- the horizontal axis represents the mZZ value.
- FIG. 18 shows the 1 H-NMR spectrum of the sulfated low molecular weight fucogalactan compound (F) of the present invention.
- FIG. 18 shows 13 C-DEPT-135.
- the spectrum is shown in Figure 19 and the mass spectrum is shown in Figure 20.
- FIG. 18 is a diagram showing a 1 H-NMR spectrum of the low molecular weight product of fuifogalatatan sulfate (F) of the present invention
- FIG. 19 is a diagram showing the spectrum of the low molecular weight product of the sulfated fucogalactan (F) of the present invention.
- FIG. 18 is a diagram showing a 1 H-NMR spectrum of the low molecular weight product of fuifogalatatan sulfate (F) of the present invention
- FIG. 19 is a diagram showing the spectrum of the low molecular weight product of the sulfated fucogalactan (F) of the present invention.
- FIG. 13 is a diagram showing a 13 C—DEPT—135 ° spectrum
- FIG. 20 is a diagram showing a mass spectrum of the sulfated fucogalactan low molecular weight compound (F) of the present invention.
- the vertical axis represents the signal intensity
- the horizontal axis represents the chemical shift value (ppm).
- the vertical axis indicates the relative intensity (%)
- the horizontal axis indicates the value.
- NMR analysis was performed to determine the entire structure of the sulfated fucogalactan fraction prepared in Example 1 (2) and the cleavage site of the sulfated fucogalactanase.
- FIG. 21 is a diagram showing a 1 H-NMR spectrum of the sulfated fucogalatatan of the present invention
- FIG. 22 is a diagram showing a 13 C-NMR spectrum of the sulfated fucogalatatan of the present invention
- FIG. 23 is a diagram showing an infrared absorption spectrum of the sulfated fucogalatan tan of the present invention.
- the vertical axis represents the signal intensity
- the horizontal axis represents the chemical shift value (ppm).
- the vertical axis represents transmittance (%)
- the horizontal axis represents wavenumber (cm ⁇ 1 ).
- the sulfated fucogalactan of the present invention has the main skeleton of the compound (D) described in Example 7 (4). Has been found to be a structure that is repeatedly bonded. Further, the bond between the repeating structures was such that the galactose of G2 was bonded to the 6-position of galactose of G4 by an i3 bond as shown in the following formula (XIII). That is, it was found that sulfated fucogalactan had a repeating structure of the following main skeleton.
- the sulfated fucogalactan-degrading enzyme of the present invention is obtained by combining D-sulfated galactose or galactose of sulphate fucogalactan with sulfate.
- the enzyme was found to be an enzyme that endogenously degrades 1-6 and 1-4 bonds between D-sulfated galactose or galactose.
- the molecular weight of the sulfated fucogalatatan of the present invention was measured under the conditions of Example 1 (3), and the average value was about 130,000. Its molecular weight distribution was about 10,000 to about 200,000.
- the HGF production-inducing activity of the sulfated fucogalactan of the present invention obtained by the method described in Example 1 (2) was measured.
- the HGF production inducing activity was measured as follows. That is, MR C-5 cell suspension (CCL 177: manufactured by Dainippon Pharmaceutical Co., Ltd.) suspended in DME medium containing 10% fetal bovine serum so as to have l ⁇ 10 5 ce 11 s / ml. cod e. 02-021) Add 500jul to a 48-well cell culture plate,
- Example 11- (2) sulfated fucogalatatan obtained by the method described in Example 11- (2) was added as a sample to a final concentration of 1, 10, and 1 0 0 ⁇ g Zm1, and the cells were further cultured for 24 hours. Collect the culture medium and use the Quantikine Human Hepatocyte Growth Factor (HGF) ELISA Kit (Funakoshi, Code. RS- 0641-
- Flavata terium sp. SA-0082 strain (FERM BP-5402) was cultured in the ultrafiltration solution according to the method described in W097Z26896, and the sulfated-fucose-containing polysaccharide mono-U obtained by the culture was degraded. 20 U of the enzyme was added and reacted at 25 ° C. for 5 days.
- the above reaction solution was subjected to ultrafiltration using an ultrafiltration machine equipped with a hollow fiber with a molecular weight of 100,000, and low-molecular-weight with the above fucose sulfate-containing polysaccharide-U degrading enzyme.
- the converted substances that is, the low-molecular-weight products of sulfated fucodarcuronomannan were thoroughly removed. At the time of ultrafiltration, water was added and finally replaced with 10 mM imidazo mono-hydrochloric acid buffer (pH 8) containing 20 OmM sodium chloride.
- Example 2 (1) 2 U of the sulfated fucogalactan degrading enzyme described in Example 2 (1) was added to the ultrafiltration internal solution, and the mixture was reacted at 25 ° C. for 5 days.
- the reaction solution is subjected to ultrafiltration using an ultrafiltration machine equipped with a 100,000 molecular weight exclusion fiber, and the substance degraded by the sulfated fucogalatatan-degrading enzyme, that is, the depolymerized sulfated fucogalactan, Thoroughly ultrafiltered.
- the buffer added at the time of ultrafiltration had the same composition as the buffer used in the above reaction solution.
- the filtrate obtained in the above (1) was collected and subjected to ultrafiltration using an ultrafiltration machine equipped with a holofiber having a molecular weight cutoff of 3000 to separate into a filtrate and a non-filtrate.
- the filtrate was concentrated to about 3 liters by a rotary evaporator and centrifuged to obtain a supernatant.
- the resulting supernatant was desalted with an electrodialyzer equipped with a membrane having an exclusion molecular weight of 300, and calcium acetate was added to the solution to a concentration of 0.1 M, and the resulting precipitate was removed by centrifugation.
- the supernatant was applied to DEAE-Cell mouth fine (resin volume: 4 liters) which had been equilibrated with 5 OmM calcium acetate in advance, and washed thoroughly with 5 OmM calcium acetate and 5 OmM sodium chloride.
- the solution of the 0.4M elution fraction was first concentrated to 15 Om1, sodium chloride was added to a concentration of 4M, and the solution was previously equilibrated with 4M sodium chloride. (Resin amount: 200 ml) and washed thoroughly with 4 M sodium chloride. The non-adsorbed sulfated saccharide fraction was collected and desalted with an electrodialyzer equipped with a membrane having an excluded molecular weight of 300 to obtain 505 ml of a desalted solution.
- the resulting desalted solution was applied to a cell-mouth Fine GCL-90 column (4.1 cm x 87 cm) in which 4 Om 1 was equilibrated with 0.2 M sodium chloride containing 10% ethanol. Gel filtration was performed. The fractionation was performed at 9.2 ml per fraction.
- the total sugar content was analyzed for all the fractions by the phenolic sulfuric acid method (Analytical Chemistry, vol. 28, p. 350 (1956)).
- the dried product of sulfated saccharide was obtained. A part of the dried product was taken and subjected to sugar composition analysis and mass spectrometry. Also, 10 mg of the dried product was replaced with heavy water by a conventional method, and subjected to NMR analysis.
- FIG. 24 shows the results of mass spectrometry of sulfated saccharides using an AP I-III mass spectrometer (Perkin Elmer Sykes), and the analysis results are shown below. That is, FIG. 24 is a diagram showing the results of mass spectrometry of the sulfated saccharide, in which the vertical axis indicates the relative intensity (%), and the horizontal axis indicates the m / z value.
- the molecular weight was 2264 ⁇ 1 in a state where all sulfate groups were converted to sodium salts.
- fucose is composed of 7 molecules and 12 sulphate groups. It was found that the acid groups were all sodium salts and the theoretical molecular weight was 2265.
- NMR analysis was performed using a J NM One 500 type nuclear magnetic resonance apparatus (manufactured by JEOL Ltd.) to determine the binding mode of fucose and the binding position of the sulfate group.
- the binding mode of the constituent sugars was determined using the HMBC method, which is a 1 H-detection heterogeneous nucleus detection method.
- the DQF-COSY method and the HOH AHA method were used for assignment of 1 H-NMR, and the HSQC method was used for assignment of 13 C-NMR.
- FIG. 25 shows the R spectrum and FIG. 26 shows the 13 C-NMR spectrum.
- the chemical shift value of ' ⁇ -NMR was expressed as the chemical shift value of dioxane was 3.53 ⁇ pm
- the chemical shift value of 13 C-NMR was expressed as the chemical shift value of dioxane was 66.5 ppm. Both measurements were performed at 60 ° C. That is, FIG. 25 is a diagram showing the 1 H-NMR spectrum of the sulfated saccharide in the 0.4 M elution fraction
- FIG. 26 is a diagram showing the 13 C-NMR spectrum of the sulfated saccharide in the 0.4 M elution fraction. It is. In FIGS. 25 and 26, the vertical axis represents the signal intensity, and the horizontal axis represents the chemical shift value (ppm). — The analysis results by NMR and 13 C—NMR are shown in Tables 12 and 13 . Table 12
- FIG. 27 is a diagram showing a 1 H-NMR spectrum of a fraction, in which the vertical axis represents signal intensity and the horizontal axis represents chemical shift value (ppm).
- the 0.6 M elution fraction had a structure in which the 0.4 M elution fraction bound several molecules. Therefore, the degraded product obtained by further decomposing the 0.6 M eluted fraction with the fucosulfate-containing polysaccharide mono-F degrading enzyme described in Example 9 (1) was analyzed by HP LC, and the reaction product was analyzed. Many of them eluted at the same position as the sulfated saccharide in the 0.4 M elution fraction of DEAE-Cellulofine described in Example 9 (2).
- HP LC The analysis conditions of HP LC are as follows.
- the 0.4 M elution fraction was converted to pullulan.
- the eluted fraction with a molecular weight of about 8500 and 0.6 M has a molecular weight of about 26000,
- the 0.6 M elution fraction was found to be a sulfated sugar trimer of the 0.4 M elution fraction. Further, the repeating binding position of the heptasaccharide residue can be determined by examining the 1 H-NMR spectrum of the eluted fraction of about 0.6M in detail, to find that the 3rd position of fucose of F in formula (XV) is ⁇ . — (1 ⁇ 3) It became clear that they were connected by a bond.
- a pentamer of sulfated saccharide represented by (XVI), that is, n 5 in the following general formula (XIV), was obtained from the low molecular weight compound of the sulfated-fucose-containing polysaccharide according to the above method.
- the sulfated sugar represented was obtained.
- a sulfated fucogalactan degrading enzyme By treating with a sulfated fucogalactan degrading enzyme, a sulfated saccharide represented by the following general formula can be obtained, which is converted into a low-molecular-weight molecule by a sulfated-ifucose-containing polysaccharide mono-F-degrading enzyme. It was confirmed that it could be done.
- the molecular weight of the sulfated polysaccharide was determined in Example 1.
- the average molecular weight is about 200,000 (the molecular weight distribution is about 10,000 ⁇ About 100,000).
- the average molecular weight is about 1.3 million (the molecular weight distribution is about 100,000 to about 20,000). 000,000).
- sulphated fucogalactan and low molecular weight products thereof which are useful as sugar chain engineering reagents or HGF production inducers.
- a novel sulfated fucogalatatan degrading enzyme which can be used for structural analysis and decomposition of the sulfated fucogalactan, and production of a reproducible low molecular weight product of sulfated fucogalactan.
- a method for producing the enzyme Also provided is a method for selectively removing sulfated fucogalactan from a mixture of sulfated fucose-containing polysaccharides using the sulfated fucogalatatan degrading enzyme of the present invention.
- the sulfated fucogalatatan-decomposing enzyme of the present invention A novel sulfated saccharose is provided by using a combination of sulfuric acid and another sulfated-fucose-containing polysaccharide degrading enzyme.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Materials Engineering (AREA)
- Polymers & Plastics (AREA)
- General Chemical & Material Sciences (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Saccharide Compounds (AREA)
- Detergent Compositions (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000601042A JP3523597B2 (ja) | 1999-02-23 | 2000-02-21 | 硫酸化フコガラクタン |
AT00904062T ATE277085T1 (de) | 1999-02-23 | 2000-02-21 | Fukogalaktan-sulfate |
EP00904062A EP1176153B1 (en) | 1999-02-23 | 2000-02-21 | Sulfated fucogalactan |
AU25751/00A AU2575100A (en) | 1999-02-23 | 2000-02-21 | Sulfated fucogalactan |
US09/913,599 US6590097B1 (en) | 1999-02-23 | 2000-02-21 | Sulfated fucogalactan |
DE60014065T DE60014065T2 (de) | 1999-02-23 | 2000-02-21 | Fucogalactan-sulfate |
CA002359839A CA2359839A1 (en) | 1999-02-23 | 2000-02-21 | Sulfated fucogalactan |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP11/44752 | 1999-02-23 | ||
JP4475299 | 1999-02-23 | ||
JP11/232809 | 1999-08-19 | ||
JP23280999 | 1999-08-19 | ||
JP35011299 | 1999-12-09 | ||
JP11/350112 | 1999-12-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000050464A1 true WO2000050464A1 (fr) | 2000-08-31 |
Family
ID=27292015
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2000/000965 WO2000050464A1 (fr) | 1999-02-23 | 2000-02-21 | Fucogalactane sulfate |
Country Status (12)
Country | Link |
---|---|
US (1) | US6590097B1 (ja) |
EP (1) | EP1176153B1 (ja) |
JP (1) | JP3523597B2 (ja) |
KR (1) | KR100601330B1 (ja) |
CN (2) | CN1305884C (ja) |
AT (1) | ATE277085T1 (ja) |
AU (1) | AU2575100A (ja) |
CA (1) | CA2359839A1 (ja) |
DE (1) | DE60014065T2 (ja) |
ES (1) | ES2225084T3 (ja) |
TW (1) | TWI247751B (ja) |
WO (1) | WO2000050464A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002022140A1 (fr) * | 2000-09-13 | 2002-03-21 | Takara Bio Inc. | Agents entretenant l'homéostase |
WO2003023036A1 (fr) * | 2001-09-05 | 2003-03-20 | Takara Bio Inc. | Gene de l'enzyme de digestion du fucogalactane sulfate |
JP2008266299A (ja) * | 2007-03-28 | 2008-11-06 | Tottori Univ | 硫酸基の脱離を抑えた硫酸化多糖の低分子化物およびその製造方法 |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1277834A1 (en) | 2000-04-21 | 2003-01-22 | Takara Bio Inc. | Glucuronofucan sulfate |
DE60202427T2 (de) | 2001-10-24 | 2005-12-29 | Takara Bio Inc., Otsu | Sulfatiertes Fucan-Oligosaccharid |
WO2003062412A1 (fr) * | 2002-01-18 | 2003-07-31 | Takara Bio Inc. | Fucane sulfate |
CN102070725B (zh) * | 2010-12-24 | 2012-07-18 | 上海中医药大学 | 一种硫酸半乳聚糖及其制备方法和应用 |
CN102633894B (zh) * | 2012-04-16 | 2013-11-06 | 中国科学院宁波材料技术与工程研究所 | 一种高浓度大型海藻生物质溶液和多糖提取液的制备方法 |
CN105017341B (zh) * | 2014-04-22 | 2018-05-15 | 华东师范大学 | 硫酸化岩藻-半乳四糖及其制备方法和应用 |
WO2018180727A1 (ja) * | 2017-03-31 | 2018-10-04 | 焼津水産化学工業株式会社 | フコース含有組成物の製造方法、そのフコース含有組成物を含有する飲食品、化粧品、トイレタリー用品、医薬部外品、及び医薬品の製造方法 |
CN107467473A (zh) * | 2017-07-04 | 2017-12-15 | 佛山科学技术学院 | 岩藻多糖用于增强生物肽贮存稳定性的用途 |
CN107987179B (zh) * | 2017-12-26 | 2020-07-07 | 中国科学院海洋研究所 | 一种低硫酸化岩藻半乳聚糖在制备免疫增强剂中的应用 |
CN112402292B (zh) * | 2020-11-26 | 2022-01-04 | 中国海洋大学 | 一种天然活性成分抗炎修复精华液及其制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997026896A1 (en) * | 1996-01-26 | 1997-07-31 | Takara Shuzo Co., Ltd. | Apoptosis inducers |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK17885D0 (da) * | 1985-01-14 | 1985-01-14 | Karlsson Karl Anders | Antiviralt middel |
CA2217746C (en) * | 1995-04-28 | 2000-04-04 | Takara Shuzo Co., Ltd. | Sugar compounds |
WO1997032010A1 (fr) * | 1996-02-29 | 1997-09-04 | Takara Shuzo Co., Ltd. | Procede pour la purification et l'elimination de virus |
-
2000
- 2000-02-21 CN CNB2004101006336A patent/CN1305884C/zh not_active Expired - Fee Related
- 2000-02-21 ES ES00904062T patent/ES2225084T3/es not_active Expired - Lifetime
- 2000-02-21 CA CA002359839A patent/CA2359839A1/en not_active Abandoned
- 2000-02-21 JP JP2000601042A patent/JP3523597B2/ja not_active Expired - Fee Related
- 2000-02-21 DE DE60014065T patent/DE60014065T2/de not_active Expired - Fee Related
- 2000-02-21 KR KR1020017008899A patent/KR100601330B1/ko not_active IP Right Cessation
- 2000-02-21 CN CNB008041571A patent/CN1191261C/zh not_active Expired - Fee Related
- 2000-02-21 WO PCT/JP2000/000965 patent/WO2000050464A1/ja active IP Right Grant
- 2000-02-21 US US09/913,599 patent/US6590097B1/en not_active Expired - Fee Related
- 2000-02-21 AT AT00904062T patent/ATE277085T1/de not_active IP Right Cessation
- 2000-02-21 AU AU25751/00A patent/AU2575100A/en not_active Abandoned
- 2000-02-21 EP EP00904062A patent/EP1176153B1/en not_active Expired - Lifetime
- 2000-02-23 TW TW089103158A patent/TWI247751B/zh active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997026896A1 (en) * | 1996-01-26 | 1997-07-31 | Takara Shuzo Co., Ltd. | Apoptosis inducers |
Non-Patent Citations (1)
Title |
---|
MIZUNO M. ET. AL.: "Fucogalactan isolated from Sarcodon aspratus elicits release of tumor necrosis factor-alpha and nitric oxide from murine macrophages", IMMUNOPHARMACOLOGY, vol. 46, no. 2, February 2000 (2000-02-01), pages 113 - 121, XP002928736 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002022140A1 (fr) * | 2000-09-13 | 2002-03-21 | Takara Bio Inc. | Agents entretenant l'homéostase |
JPWO2002022140A1 (ja) * | 2000-09-13 | 2004-03-04 | タカラバイオ株式会社 | 恒常性維持剤 |
WO2003023036A1 (fr) * | 2001-09-05 | 2003-03-20 | Takara Bio Inc. | Gene de l'enzyme de digestion du fucogalactane sulfate |
EP1424396A4 (en) * | 2001-09-05 | 2006-08-16 | Takara Bio Inc | GENE OF THE ENZYME OF DIGESTION OF FUCOGALACTANE SULFATE |
US7217552B2 (en) | 2001-09-05 | 2007-05-15 | Takara Bio Inc. | Sulfated fucogalactan digesting enzyme gene |
US7410786B2 (en) | 2001-09-05 | 2008-08-12 | Takara Bio. Inc. | Sulfated fucogalactan digesting enzyme gene |
JP2008266299A (ja) * | 2007-03-28 | 2008-11-06 | Tottori Univ | 硫酸基の脱離を抑えた硫酸化多糖の低分子化物およびその製造方法 |
Also Published As
Publication number | Publication date |
---|---|
ATE277085T1 (de) | 2004-10-15 |
JP3523597B2 (ja) | 2004-04-26 |
EP1176153A1 (en) | 2002-01-30 |
CN1305884C (zh) | 2007-03-21 |
CN1341126A (zh) | 2002-03-20 |
ES2225084T3 (es) | 2005-03-16 |
TWI247751B (en) | 2006-01-21 |
CA2359839A1 (en) | 2000-08-31 |
DE60014065D1 (de) | 2004-10-28 |
KR20020002372A (ko) | 2002-01-09 |
EP1176153B1 (en) | 2004-09-22 |
DE60014065T2 (de) | 2005-10-06 |
AU2575100A (en) | 2000-09-14 |
US6590097B1 (en) | 2003-07-08 |
CN1191261C (zh) | 2005-03-02 |
EP1176153A4 (en) | 2002-08-07 |
KR100601330B1 (ko) | 2006-07-14 |
CN1670027A (zh) | 2005-09-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3555766B2 (ja) | アポトーシス誘発剤 | |
WO2000050464A1 (fr) | Fucogalactane sulfate | |
WO1996034004A1 (fr) | Composes de sucre | |
JP4223550B2 (ja) | ウイルスの精製および除去方法 | |
JP2009050271A (ja) | 硫酸化グルクロノフカン | |
US20120157669A1 (en) | K5 heparosan fermentation and purification | |
JP4262601B2 (ja) | 硫酸化フカン | |
JP3854063B2 (ja) | 糖化合物 | |
JP4073787B2 (ja) | 硫酸化フコグルクロノマンナン | |
WO1996016166A1 (fr) | Nouvelle hydrolase de keratane sulfate | |
JP3497817B2 (ja) | 硫酸化フコガラクタン分解酵素 | |
KR100903771B1 (ko) | 황산화 푸칸 올리고당 | |
JP4119890B2 (ja) | ナマコ由来硫酸化フカン分解酵素 | |
TWI237026B (en) | Fucose sulfuric acid-containing polysaccharide, the preparing method thereof and the anti-cancer agent and preventing agent for inducement of cancer | |
WO1998001537A1 (fr) | Compositions cellulaires | |
JP3503821B2 (ja) | エンド型フコース硫酸含有多糖分解酵素 | |
JP2001226408A (ja) | フコース硫酸含有多糖 | |
JP2001226407A (ja) | フコース硫酸含有多糖 | |
JP2001224394A (ja) | 低分子化物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 00804157.1 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2359839 Country of ref document: CA Ref document number: 2359839 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020017008899 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09913599 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000904062 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1020017008899 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2000904062 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 2000904062 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1020017008899 Country of ref document: KR |